Related Experiment Video
Updated: Sep 28, 2026
Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer
Published on: February 27, 2026
Surgical resection of multifocal non-small cell lung cancer is associated with prolonged survival
Richard J Battafarano1, Bryan F Meyers, Tracey J Guthrie
1Department of Surgery, Washington University School of Medicine, St. Louis, Missouri 63110-1013, USA. battafarano@msnotes.wustl.edu
Background:
Revisions in the international system for the staging of lung cancer, adopted in 1997, assigned the T4 descriptor to separate tumor nodules in the same lobe and the M1 descriptor to tumor nodules in a different lobe. Consequently, these changes shifted the stage of patients with these lesions to stage IIIB or stage IV. The goal of this review was to determine the impact of multifocal non-small cell lung cancer on survival.
Methods:
A database analysis of our cardiothoracic surgery tumor registry was performed to identify all patients who underwent surgical resection of non-small cell lung cancer (NSCLC), who were ultimately determined to have pathologically node-negative disease from 1994 to 1999. All pathology reports were individually reviewed. Survival data were collected on each patient from the date of surgery with a mean duration of follow-up of 46.3 months. Kaplan Meier actuarial survival was determined for all patients.
Results:
Forty-four patients were identified who underwent complete resection of multiple NSCLC tumors. During this same period, 504 patients underwent complete resection of stage I NSCLC tumors. The 3-year actuarial survival for patients with T1/N0/M0 tumors was 79.6%. In comparison with patients with T1/N0/M0 tumors, the 3-year actuarial survival rates of patients with T2/N0/M0 tumors (72.3%, p = 0.056), T4/N0/M0 tumors (66.5%, p = 0.058), and T1 to T2/N0/M1 tumors (63.6%, p = 0.201) were lower. However, these differences did not achieve statistical significance.
Conclusions:
Although there was a trend toward decreased survival in patients with multifocal NSCLC compared with patients with stage I NSCLC, this did not achieve statistical significance. Importantly, survival in these subgroups of patients with stage IIIB or stage IV disease (stage determined solely on the basis of multifocal NSCLC) is better than the survival reported in the series that formed the foundation for these staging changes. These data support complete surgical resection of multifocal lung tumors in patients with node-negative NSCLC.